Published online before print January 22, 2007, doi: 10.1161/CIRCULATIONAHA.106.641407
(Circulation. 2007;115:501-508.)
© 2007 American Heart Association, Inc.
Vascular Medicine |
FTY720, a Synthetic Sphingosine 1 Phosphate Analogue, Inhibits Development of Atherosclerosis in Low-Density Lipoprotein Receptor–Deficient Mice
From the Institut für Klinische Chemie und Laboratoriumsmedizin, Westfälische Wilhelms-Universität, Münster, Germany (J.-R.N., G.A.), Leibniz-Institut für Arterioskleroseforschung an der Universität Münster, Münster, Germany (J.-R.N., G.A.), Division of Biopharmaceutics, Leiden/Amsterdam Center for Drug Research, Leiden University, Leiden, the Netherlands (M. Bot, T.v.B., E.A.L.B.), Klinik und Poliklinik für Anästhesiologie und Operative Intensivmedizin, Experimentelle und Klinische Hämostaseologie, Universitätsklinik, Münster, Germany (M. Brodde), Australian Bioanalytical Services Pty Ltd, Princess Alexandra, Hospital, Brisbane, Australia (P.J.T., P.S.), Department of Clinical Pharmacology, Princess Alexandra Hospital, Brisbane, Australia (P.J.T.), and Transplantation and Immunology, Novartis Institutes for BioMedical Research, Basel, Switzerland (V.B.).
Correspondence to Jerzy-Roch Nofer, MD, MBA, Institut für Klinische Chemie und Laboratoriumsmedizin, Westfälische Wilhelms-Universität Münster, Albert Schweizer Str 33, D-48129 Münster, Germany. E-mail nofer{at}uni-muenster.de
Received May 22, 2006; accepted November 15, 2006.
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background— Numerous in vitro studies suggest that sphingosine 1-phosphate (S1P), a bioactive lysosphingolipid associated with high-density lipoproteins, accounts at least partly for the potent antiinflammatory properties of high-density lipoprotein and, thereby, contributes to the antiatherogenic potential attributed to high-density lipoproteins. The present study was undertaken to investigate whether modulation of S1P signaling would affect atherosclerosis in a murine model of disease.
Methods and Results— Low-density lipoprotein receptor–deficient mice on a cholesterol-rich diet were given FTY720, a synthetic S1P analogue, at low (0.04 mg/kg per day) or high (0.4 mg/kg per day) doses for 16 weeks. FTY720 dose-dependently reduced atherosclerotic lesion formation, both in the aortic root and brachiocephalic artery, and almost completely blunted necrotic core formation. Plasma lipids remained unchanged during the course of FTY720 treatment. However, FTY720 lowered blood lymphocyte count (at a high dose) and significantly interfered with lymphocyte function, as evidenced by reduced splenocyte proliferation and interferon-
levels in plasma. Plasma concentrations of proinflammatory cytokines such as tumor necrosis factor-
, interleukin (IL)-6, IL-12, and regulated on activation normal T cell expressed and secreted were reduced by FTY720 administration. Moreover, lipopolysaccharide-elicited generation of nitrite/nitrate and IL-6—two markers of classical (M1) macrophage activation—was inhibited, whereas IL-4–induced production of IL-1–receptor antagonist, a marker of alternative (M2) macrophage activation, was augmented in peritoneal macrophages from FTY720-treated low-density lipoprotein receptor–deficient mice.
Conclusions— The present results demonstrate that an S1P analogue inhibits atherosclerosis by modulating lymphocyte and macrophage function, and these results are consistent with the notion that S1P contributes to the antiatherogenic potential of high-density lipoprotein.
Key Words: FTY 720 • sphingosine 1-phosphate • lipoproteins • inflammation • atherosclerosis
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The biologically active lysosphingolipid sphingosine 1-phosphate (S1P) is an important lipid mediator generated from phospholipids on cell activation and is present in plasma and extracellular fluid in high nanomolar concentrations.1,2 A large body of evidence has documented the pleiotropic effects of S1P in various cell types and organs. S1P was demonstrated to interfere with proliferation, migration, and cytokine secretion by lymphocytes and to prevent their recirculation from lymphoid compartments to peripheral sites of antigen presentation.3,4 These immunomodulatory activities likely account for the beneficial effects exerted by S1P and its analogues in animal models of inflammatory diseases such as ulcerating colitis, viral myocarditis, endotoxin-induced lung injury, or autoimmune encephalomyelitis.5–8 In the vasculature, S1P was found to affect survival, proliferation, migration, and activation of endothelial and smooth-muscle cells and thus regulate vascular development and vessel contraction.1,9 S1P evokes these diverse cellular responses by binding to members of a family of homologous G-protein–coupled receptors designated as S1P receptors. S1P1 and S1P4 were found to preponderate in lymphocytes, whereas other cells present in the vascular wall mainly express S1P1, S1P2, and S1P3 receptors.9,10
Clinical Perspective p 508
Numerous epidemiological and clinical studies have documented an inverse relationship between high-density lipoprotein (HDL) and the progression of atherosclerosis, but the mechanisms underlying the antiatherogenic effects of HDL are not entirely clear. Recent investigations have revealed that HDL serves as a carrier of biologically active lysosphingolipids, including S1P.11,12 Moreover, S1P in vitro was found to emulate several antiatherogenic effects attributed to HDL, including inhibition of endothelial apoptosis and stimulation of cell movement, inhibition of the expression of adhesion molecules, and stimulation of nitric oxide generation.13–15 Although these data may point to an atheroprotective activity of S1P, the effect of HDL-associated lysosphingolipids on atherosclerosis has not yet been addressed in an in vivo setting. In the present study, we evaluated the effect of 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diolhydrochloride (FTY720), a high-affinity agonist of S1P1, S1P3, S1P4, and S1P5 receptors,16 on the development of diet-induced atherosclerosis in low-density lipoprotein (LDL) receptor–deficient (LDL-R–/–) mice. FTY720 was originally derived as an immunomodulatory compound exerting beneficial effects in several animal models of chronic inflammation.17,18 In addition, FTY720 was reported to interact with endothelial cells and to exert several potentially antiatherogenic effects, such as enhancing adherens junction assembly and endothelial barrier function or promoting nitric oxide generation and vasorelaxation.18,19 Here, we show that FTY720 retards the development of atherosclerosis independently of changes in total plasma or HDL cholesterol.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Additional details are provided in the online-only Data Supplement.
FTY720 Determination, Application, and Distribution
FTY720 was determined in full blood and fractionated plasma lipoproteins using high-performance liquid chromatography-tandem mass spectrometry, exactly as described previously.20 This compound shows few toxic effects in either animal or human studies.21,22 Accordingly, no adverse effects or significant changes in body weight were observed in the present investigation in treated animals during the FTY720-application period. Because of rapid initial absorption (time of occurrence for maximum drug concentration 
2 to 24 hours), extensive volume of distribution, and exceptionally long elimination half-life (7 days), FTY720 blood concentrations remain stable after administration, with little fluctuation during the dosing interval.21–23 Consistent with these pharmacokinetic properties, twice- or thrice-weekly administration of FTY720 is sufficient to suppress inflammatory processes in various mouse models.24,25 In the present study, we found that repeated intraperitoneal injection of the compound (20 µg/LDL-R–/– mouse, thrice weekly) produces FTY720 plasma concentrations of 67.5±8.7 ng/mL, which is within the known therapeutic concentration range.23 Examination of FTY720 distribution among lipoprotein fractions isolated from LDL-R–/– mouse plasma spiked with 50 ng/mL of the compound revealed that 32%, 24%, and 44% were present in very-low-density lipoprotien, LDL, and HDL, respectively. Minor amounts of FTY720 were found in plasma fractions containing no lipoproteins.
Animals
Female LDL-R–/– mice on a C57BL/6J background were purchased from The Jackson Laboratory, Bar Harbor, Me, and housed under pathogen-free conditions at the Center for Animal Studies of the University Clinic of Münster. Mice (8 weeks old, 20 to 25 g, female) were put on an atherogenic high-fat diet (1.25% cholesterol, 7% cocoa butter; Harlan Winkelmann, Borchen, Germany) for 16 weeks. Animals were separated randomly into 3 groups (n=8 mice/group). The first and second groups received 3 weekly intraperitoneal injections of 2.0 µg FTY720 (0.04 mg/kg per day; low dose) and 20 µg FTY720 per mouse (approximately 0.4 mg/kg per day; high dose), and the third control group was injected with the same volume (0.1 mL) of saline. Blood samples for blood cell count, lipid, and lipoprotein profiling were collected retroorbitally at days 0, 7, 30, 60, and 90 of the study. At the end of the 16-week treatment period, mice were bled by retroorbital vein puncture under complete anesthesia with ketamine. Peritoneal macrophages were isolated, and tissues were collected for further analysis. The experimental protocol was approved by local animal research committee.
Histology and Lesion Analysis
Exsanguinated animals were subjected to in situ perfusion fixation with formaldehyde (4% weight/volume) through the left cardiac ventricle. For analysis of spontaneous atherosclerosis, the aortic root and the brachiocephalic artery were removed and embedded in Tissue-Tek. Cryosections of the brachiocephalic artery (5- µm thick) were prepared and stained with hematoxylin (Sigma Diagnostics, Zwijndrecht, the Netherlands) and eosin (Merck Diagnostica, Darmstadt, Germany). For the aortic root, 10-µm cryosections were prepared and stained with Oil Red O (Sigma, St. Louis, Mo). Cross-sections with maximal stenosis were used for morphometric analysis on a DM-RE microscope with Leica Qwin image-analysis software (Leica Microsystems B.V., Rijswijk, the Netherlands), as described previously.26,27
Corresponding sections were stained immunohistochemically with antibodies directed against mouse macrophages (monoclonal mouse IgG2a, clone monocyte + macrophage antibody-2 [MOMA-2], dilution 1:50; Sigma Diagnostics), vascular smooth muscle cells (monoclonal mouse IgG2a, clone 1A4, dilution 1:50; Sigma), and lymphocytes (purified antimouse CD3 molecular complex, 17A2, dilution 1:50; BD Biosciences Pharmingen, San Diego, Calif). Sections were stained for collagen using Picrosirius Red (Sigma). Macrophage-, vascular smooth muscle cell-, and collagen-positive areas were determined by computer-assisted color-gated measurement and were related to the total intimal surface area. For lymphocytes, the number of CD3-positive cells was assessed in 5 consecutive sections, and averages were used for analysis.
Lipid Analysis and Lipoprotein Fractionation
Plasma total cholesterol, HDL cholesterol, and triglycerides were determined enzymatically using commercially available kits (Roche, Mannheim, Germany). Plasma lipoproteins were fractionated using the Smart chromatographic system (Pharmacia, Uppsala, Sweden).
Cytokine Determination
Plasma tumor necrosis factor- (TNF-), interleukin (IL)-6, and interferon- (IFN-) levels were quantified by commercially available ELISA (R&D Systems, Wiesbaden, Germany). Semiquantitative determination of proinflammatory cytokines was performed using a Cytokine Array I from Raybiotech Inc (Norcross, Ga).
Leukocyte Differential Count and Lymphocyte Subtyping
Differential leukocyte count was performed manually (Pappenheim staining) in a routine hospital laboratory. Lymphocyte subtyping was performed by flow cytometry.
Splenocyte Proliferation
The [3H]thymidin incorporation rate was used to estimate proliferation of splenocytes stimulated with phorbol myristate acetate or concanavalin A.
Functional Characterization of Peritoneal Macrophages
Peritoneal macrophages were stimulated with lipopolysaccharide (LPS) or IL-4. Concentrations of nitrite, IL-6, and IL-1RA in the cell medium were determined by commercially available reagents (Promega, Madison, Wis; R&D Systems, Wiesbaden, Germany).
Statistical Analysis
Values are expressed as mean±SD unless indicated otherwise. Comparisons between control and treated mice were made by 1- or 2-way ANOVA for independent samples or repeated measures as appropriate. Non-Gaussian distributed data were analyzed by Kruskall–Wallis test. Pairwise comparisons of sample means were performed with Tukey HSD test. Trend significance analysis was performed with linear regression using actual doses as independent variables with ANOVA for the significance of the obtained correlation coefficient. A level of P<0.05 was considered significant.
The authors had access to and take responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
FTY720 Retards Atherosclerotic Lesion Development in LDL-R–/– Mice
Aortic root and brachiocephalic plaque size was determined as a measure of the effect of FTY720 on atherogenesis in high-fat diet–fed LDL-R–/– mice. Morphometric quantification of Oil Red O–stained aortic root lesions revealed decreased atherosclerosis after FTY720 treatment, with a significant trend toward reduction of the lesion area with increasing doses of the compound (r=–0.508; P=0.011; Figure 1A). The group receiving low doses of FTY720 (approximately 0.04 mg/kg per day) showed a slight decrease in lesion area that did not reach statistical significance. However, high doses of FTY720 (approximately 0.4 mg/kg per day) led to significant reductions in lesion area compared with control mice. A similar pattern was observed for the brachiocephalic artery plaques (Figure 1B); because the variance in brachiocephalic vessel area was rather high, the intima/media ratio (reflecting the relative vessel-wall thickening) and the intima/lumen ratio (reflecting degree of stenosis) were considered to be more reliable parameters. Both ratios were found to be significantly reduced after FTY720 treatment.
|
FTY720 Affects Atherosclerotic Plaque Morphology
Although FTY720 treatment attenuated lesion formation in the aortic root as well as the brachiocephalic artery, it did not significantly affect the plaque collagen or anti-smooth muscle antibody content (not shown). Plaques from mice treated with FTY720 at a high dose (FTY-HD mice) tended to be richer in MOMA-positive macrophages, but this tendency could be completely ascribed to a lower progression stage of these plaques (Figure 2A). Indeed, FTY treatment dose-dependently impaired necrotic core formation (P<0.01 in high dose–treated compared with untreated mice, Figure 2B). Further analysis showed that high-dose FTY720 treatment substantially reduced intraplaque content of CD3-positive T cells (Figure 2C). Taken together, our data suggest that FTY720 treatment slows down necrotic core formation and dampens intraplaque inflammation, 2 major determinants of reduced plaque stability.
|
FTY720 Does Not Affect Plasma Lipid Profile
To assess potentially antiatherogenic effects of FTY720 on lipid metabolism, we monitored plasma lipid profiles in LDL-R–/– animals during the treatment period. As shown in Figure 3, total cholesterol, triglycerides, and HDL cholesterol concentrations in LDL-R–/– mice on chow diet were approximately 300 mg/dL, 150 mg/dL, and 120 mg/dL, respectively. When fed an atherogenic diet, total cholesterol, triglycerides, and HDL cholesterol levels were increased to approximately 1400 mg/dL, 450 mg/dL, and 400 mg/dL, respectively. No significant changes (by repeated-measures ANOVA) in the plasma lipid profile were observed between treatment groups (Figure 3D).
|
), low-dose (n=8 mice; 
), or high-dose (n=8 mice; 
) FTY-720 treatment, and total cholesterol (A), triglyceride (B), and HDL cholesterol (C) levels were determined using routine laboratory procedures. D, Demonstration of chromatographic lipoprotein profile in plasma obtained from animals treated with high (
FTY720 Affects Lymphocyte Count and Profile
To investigate whether FTY720 affects lesion formation by modulating peripheral immunity, we monitored leukocyte abundance and analyzed lymphocyte subpopulations by flow cytometry. As shown in Figure 4, the relative amount of lymphocytes was markedly decreased, whereas that of neutrophils was relatively increased in LDL-R–/– mice treated with high doses of FTY720 (P<0.001 by repeated-measures ANOVA). In addition, a rise in B-cell number (CD19+) and a dramatic drop in T-helper to cytotoxic T-cell ratio (CD4+/CD8+) were registered in FTY720-HD–treated animals (P<0.001 by repeated-measures ANOVA). In contrast, low doses of FTY720 did not alter the leukocyte profile or the B-cell counts, but they significantly decreased the CD4+/CD8+ ratio (P<0.001 by repeated-measures ANOVA) (Figure 4).
|
FTY720 Suppresses Lymphocyte Proliferation
In addition to lymphocyte counts and subset pattern, we also addressed the influence of FTY720 on lymphocyte function. To this end, murine splenocytes from control and FTY720-treated animals were stimulated with phorbol myristate acetate (10.0 µmol/L) or concanavalin A (2.0 µg/mL), and the proliferation rate was determined in a [3H]thymidin-incorporation assay. As shown in Figure 5, both agonists potently stimulated proliferation of splenic cells from control animals. By contrast, the mitotic response of splenocytes obtained from LDL-R–/– mice treated with either high or low FTY-720 doses to phorbol myristate acetate or concanavalin A was almost completely abrogated.
|
FTY720 Modulates Plasma Cytokine Profile
Because lymphocyte activation may be associated with an altered secretion of several inflammatory mediators, we next examined the effects of FTY720 treatment on the plasma cytokine profile. At both doses, FTY720 treatment of LDL-R–/– mice led to a marked reduction of the plasma levels of IL-12 and regulated on activation normal T cell expressed and secreted—2 key mediators of lymphocyte function (Figure 6A). In addition, plasma levels of soluble TNF-R—a member of the inflammatory cytokine network—were reduced by FTY720 treatment. Plasma concentrations of IFN-—a cytokine released from lymphocyte on activation—were seen to be dramatically decreased in low- and high-dose FTY720–treated versus control animals (Figure 6B). Finally, FTY720 substantially reduced plasma concentrations of IL-6 and TNF-—2 markers of macrophage-dependent inflammatory processes (Figure 6C).
|
FTY720 Modulates Macrophage Activation
Because FTY720 reduced the plasma levels of macrophage-derived proinflammatory cytokines, its effect on macrophage activation by proinflammatory stimuli was investigated as well. To this purpose, peritoneal macrophages obtained from control and FTY720-treated animals were stimulated for 24 hours, with LPS inducing a classical (M1) type of macrophage activation characterized by high nitric oxide and IL-6 production, or with IL-4 promoting an alternative (M2) type of macrophage activation, with high secretion levels of the antiinflammatory cytokine IL-1RA.28 As demonstrated in Figure 7, stimulation of macrophages with LPS induced the secretion of the M1 mediators IL-6 and nitric oxide, whereas the release of IL-1RA—an M2-type activation marker—was markedly elevated in IL-4–elicited macrophages. Both basal and LPS-stimulated production of IL-6 and nitric oxide were attenuated in macrophages obtained from FTY720 treated LDL-R–/– mice. Conversely, treatment with FTY720 significantly amplified both basal and IL-4–induced release of IL-1RA from macrophages. Collectively, these results indicate that long-term treatment of LDL-R–/– mice with FTY720 favors an M2-type macrophage-activation profile.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The recent identification of S1P as an integral component of HDL has generated widespread interest in the potential antiatherogenic effects of this compound.13 However, the effects of S1P on the development of atherosclerotic lesions in animal models of atherosclerosis have not been addressed to date. Here, we demonstrate that FTY720, a synthetic analogue of S1P and a potent agonist of 4 out of 5 S1P receptors (S1P1, S1P3, S1P4, and S1P5),16 preferentially distributes into HDL and inhibits the development of atherosclerotic lesions in LDLR–/– mice on a cholesterol-rich diet. These observations provide direct evidence for an atheroprotective effect of S1P-receptor agonists and are consistent with the notion that S1P contributes to the antiatherogenic potential attributed to HDL.
Because FTY720 did not change HDL and total cholesterol levels or the lipoprotein profile, its capacity to protect against atherosclerosis seems to be independent of alterations in lipid metabolism. It might be related to the ability of this compound to interfere with atherosclerosis-relevant functions of inflammatory cells. FTY720 was previously shown to produce lymphopenia by sequestering lymphocytes from blood into lymph nodes, thereby preventing their recruitment into sites of inflammation.18,29 In the present study, we were able to recapitulate FTY720-induced lymphopenia in LDL-R–/– deficient mice and, in addition, to demonstrate markedly reduced CD3+-cell infiltration into atherosclerotic lesions. Lymphocytes are crucially involved in the propagation of inflammatory processes within the arterial wall, and T-cell deficiency has been repeatedly reported to attenuate atherogenesis.30–32 Thus, it is conceivable that the decreased lymphocyte availability partly accounts for the reduction of atherosclerosis seen in animals treated with high doses of FTY720. In addition, long-term FTY720 administration favorably affected the lymphocyte subset profile by disproportionally reducing proatherogenic CD4+ T cells33,34
Although FTY720 most effectively reduced atherosclerosis when administered at high doses, the atheroprotective effects of this compound were still evident after low doses of FTY720 that only slightly affected blood lymphocyte counts and T-cell subset pattern. Apparently, altered T-cell trafficking and sequestration cannot be held fully accountable for the reduced atherosclerosis in FTY720-treated animals. S1P1- and S1P4-receptor–mediated signaling was previously demonstrated in vitro to suppress the response of lymphocytes to mitogenic stimuli and the secretion of T cell–specific cytokines, including IL-2 and IFN-.35–37 In the present study, splenocyte proliferation and IFN- levels in plasma were sharply reduced after FTY720 treatment, indicating some interference with lymphocyte function under in vivo conditions. The suppression of IFN- production after long-term FTY720 administration may be instrumental in the antiatherogenic effects exerted by this compound. IFN- is abundantly present in atherosclerotic lesions, and substantially reduced plaque formation was observed in IFN-– or IFN--R–deficient ApoE–/– mice.38–41 IFN- is critically engaged in the development of Type 1 T-cell polarization. The present data demonstrate that other important mediators of lymphocyte type 1 polarization, such as IL-12 and regulated on activation normal T cell expressed and secreted, are decreased in FTY720-treated animals, suggesting that signaling via S1P receptors may attenuate Th1 immune responses. In this regard, our data agree with previous findings showing decreased levels of Th1 cytokines and Th1 immunoglobulin isotypes in animals treated with FTY720 or overexpressing S1P1 receptor.42,43 In addition, both S1P and FTY720 were shown to suppress the production of Th1 cytokines by isolated T cells while enhancing the production of Th2 cytokines such as IL-10.28,44 Because Th1 cells are considered to represent a particularly proatherogenic subset within the CD4+ T-cell population,45 FTY720 may be expected to impair atherogenesis by attenuating Th1 response and by skewing the immune response toward Th2 response.
In contrast to lymphocytes, accumulation of macrophages within the atherosclerotic plaque was not significantly changed in FTY720-treated animals, although the necrotic core formation in FTY720-treated mice was dose-dependently blunted, and the plaque phenotype in these mice was less progressed. Analogous to lymphocytes, however, FTY720 did modulate macrophage function in vivo, even at low doses. Plasma levels of proinflammatory cytokines such as TNF-, TNF-R, and IL-6, which are abundantly secreted by activated macrophages, were markedly reduced in LDL-R–/– mice treated with low or high doses of FTY720. In addition, peritoneal macrophages from FTY720-treated animals displayed a decreased response to LPS, an established inducer of classical (M1)-type macrophage activation. Conversely, long-term administration of FTY720 enhanced the IL-4–elicited production of IL-1RA, a marker of alternative (M2)-type macrophage activation. Collectively, these observations suggest that the FTY720-induced polarization of lymphocytes toward a Th2 response is paralleled by a complementary M1
M2 switch in macrophages. Because M2 macrophages constitute a rich source of antiinflammatory factors,28 these cells may dampen inflammatory responses within the vascular wall and, thereby, counteract the formation of atherosclerotic lesions.
S1P signals through 5 cognate S1P receptors, 4 of which (S1P1– 4) were seen to be expressed in the vasculature and may be potentially involved in the pathogenesis of atherosclerosis. A contribution of S1P2 can be excluded because FTY720 is only a very poor agonist of this receptor. The preponderance of S1P1 and S1P4 in cells of hematopoietic origin such as lymphocytes and macrophages—both major targets of FTY720—suggests that these 2 receptors may play a prominent role in the atheroprotective activity of FTY720. This notion is further strengthened by the observation that S1P1 is a preferential FTY720-binding partner and signal-transducing receptor.16 Recent studies have suggested that S1P1 is mainly responsible for S1P-elicited antiinflammatory responses such as inhibition of leukocyte adhesion to endothelium, vascular permeability, or T-cell trafficking.46–48 In addition, S1P1 mediates protective effects of FTY720 on ischemia-reperfusion injury.49,50 In this context, it is of interest that HDL effectively prevents ischemia-reperfusion injury in the kidney and heart and that a substantial portion of these effects is not attributable to proteins present in HDL because it is not fully mimicked by apolipoprotein A-I–containing liposomes.51,52 Whereas antiatherogenic effects of HDL, S1P, and FTY720 might be primarily mediated by S1P1, the involvement of other S1P receptors cannot be entirely dismissed. For instance, S1P- and FTY720-induced signaling via S1P3 receptors has been previously demonstrated to stimulate NO generation and to inhibit proinflammatory NADPH-oxidase activity in endothelial and smooth-muscle cells, respectively12,19 (Nofer et al, unpublished observations, 2005). In addition, S1P3 has been shown to serve as a functional HDL receptor, because its endothelial nitric oxide synthase-stimulating and NADPH-oxidase–inhibiting effects were markedly attenuated in S1P3-deficient mice. Recently, S1P3 was also suggested to mediate the protective affects of HDL on myocardial injury in mice.53 Our present study emphasizes the necessity of further research to delineate the exact contribution of the individual S1P-signaling pathways to the atheroprotective effects of HDL, S1P, and FTY720, and warrants further evaluation of more selective S1P-receptor agonists as potential HDL surrogates and modulators of human cardiovascular disease.
In conclusion, the present data show that signaling via S1P receptors attenuates the development of atherosclerosis in an animal model of disease, and this effect can be attributed to modulation of the function of T cells and macrophages. Because S1P is an integral component of HDL, our results strengthen the notion that this lysosphingolipid significantly contributes to antiinflammatory and antiatherogenic effects exhibited by HDL.
|
Acknowledgments |
|---|
The authors are indebted to Dr Helmut Schulte for valuable advice in statistical analysis and Dr Claus Langer for his help in preparation of peritoneal macrophages. The expert technical assistance of Alois Rötrige is gratefully acknowledged.
Sources of Funding
This work was supported in part by the ADUMED Foundation for Medical Research to Dr Nofer and the Dutch Thrombosis Foundation (TSN2004.001) and the Netherlands Heart Foundation (D2003T201) to Dr Biessen.
Disclosures
None.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Spiegel M, Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol. 2003; 4: 397–407.[CrossRef][Medline] [Order article via Infotrieve]
2. Gardell SE, Dubin AE, Chun J. Emerging medicinal roles for lysophospholipid signaling. Trends Mol Med. 2006; 12: 65–75.[CrossRef][Medline] [Order article via Infotrieve]
3. Rosen H, Goetzl EJ. Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network. Nat Rev Immunol. 2005; 5: 560–570.[CrossRef][Medline] [Order article via Infotrieve]
4. Goetzl EJ, Rosen H. Regulation of immunity by lysosphingolipids and their G protein-coupled receptors. J Clin Invest. 2004; 114: 1531–1537.[CrossRef][Medline] [Order article via Infotrieve]
5. Miyamoto T, Matsumori A, Hwang MW, Nishio R, Ito H, Sasayama S. Therapeutic effects of FTY720, a new immunosuppressive agent, in a murine model of acute viral myocarditis. J Am Coll Cardiol. 2001; 37: 1713–1718.
6. Peng X, Hassoun PM, Sammani S, McVerry BJ, Burne MJ, Rabb H, Pearse D, Tuder RM, Garcia JG. Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury. Am J Respir Crit Care Med. 2004; 169: 1245–1251.
7. Webb M, Tham CS, Lin FF, Lariosa-Willingham K, Yu N, Hale J, Mandala S, Chun J, Rao TS. Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice. J Neuroimmunol. 2004; 153: 108–121.[CrossRef][Medline] [Order article via Infotrieve]
8. Fujii R, Kanai T, Nemoto Y, Makita S, Oshima S, Okamoto R, Tsuchiya K, Totsuka T, Watanabe M. FTY720 suppresses CD4+CD44highCD62L- effector memory T cell-mediated colitis. Am J Physiol Gastrointest Liver Physiol. 2006; 291: G267–G274.
9. Alewijnse AE, Peters SL, Michel MC. Cardiovascular effects of sphingosine-1-phosphate and other sphingomyelin metabolites. Br J Pharmacol. 2004; 143: 666–684.[CrossRef][Medline] [Order article via Infotrieve]
10. Anliker B, Chun J. Lysophospholipid G protein-coupled receptors. J Biol Chem. 2004; 279: 20555–20558.
11. Murata N, Sato K, Kon J, Tomura H, Yanagita M, Kuwabara A, Ui M, Okajima F. Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptor-mediated actions. Biochem J. 2000; 352: 809–815.[CrossRef][Medline] [Order article via Infotrieve]
12. Nofer JR, van der Giet M, Tolle M, Wolinska I, von Wnuck Lipinski K, Baba HA, Tietge UJ, Godecke A, Ishii I, Kleuser B, Schafers M, Fobker M, Zidek W, Assmann G, Chun J, Levkau B. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest. 2004; 113: 569–581.[CrossRef][Medline] [Order article via Infotrieve]
13. Nofer JR, Assmann G. Atheroprotective effects of high-density lipoprotein-associated lysosphingolipids. Trends Cardiovasc Med. 2005; 15: 265–271.[CrossRef][Medline] [Order article via Infotrieve]
14. Kimura T, Sato K, Kuwabara A, Tomura H, Ishiwara M, Kobayashi I, Ui M, Okajima F. Sphingosine 1-phosphate may be a major component of plasma lipoproteins responsible for the cytoprotective actions in human umbilical vein endothelial cells. J Biol Chem. 2001; 276: 31780–31785.
15. Kimura T, Sato K, Malchinkhuu E, Tomura H, Tamama K, Kuwabara A, Murakami M, Okajima F. High-density lipoprotein stimulates endothelial cell migration and survival through sphingosine 1-phosphate and its receptors. Arterioscler Thromb Vasc Biol. 2003; 23: 1283–1288.
16. Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, Hof R, Bruns C, Prieschl E, Baumruker T, Hiestand P, Foster CA, Zollinger M, Lynch KR. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem. 2002; 277: 21453–21457.
17. Chiba K. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors. Pharmacol Ther. 2005; 108: 308–319.[CrossRef][Medline] [Order article via Infotrieve]
18. Brinkmann V, Cyster JG, Hla T. FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am J Transplant. 2004; 4: 1019–1025.[CrossRef][Medline] [Order article via Infotrieve]
19. Tolle M, Levkau B, Keul P, Brinkmann V, Giebing G, Schonfelder G, Schafers M, von Wnuck Lipinski K, Jankowski J, Jankowski V, Chun J, Zidek W, Van der Giet M. Immunomodulator FTY720 Induces eNOS-dependent arterial vasodilatation via the lysophospholipid receptor S1P3. Circ Res. 2005; 96: 913–920.
20. Salm P, Warnholtz CR, Lynch SV, Taylor PJ. Measurement and stability of FTY720 in human whole blood by high-performance liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry. J Chromatography B. 2006; 848: 157–163.
21. Kahan B. Update on pharmacokinetic/pharmacodynamic studies with FTY720 and sirolimus. Ther Drug Monit. 2002; 24: 47–52.[CrossRef][Medline] [Order article via Infotrieve]
22. Kovarik JM, Schmouder RL, Slade AJ. Overview of FTY720 clinical pharmacokinetics and pharmacology. Ther Drug Monit. 2004; 6: 585–587.
23. Kahan BD, Karlix JL, Ferguson RM, Leichtman AB, Mulgaonkar S, Gonwa TA, Skerjanec A, Schmouder RL, Chodoff L. Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study. Transplantation. 2003; 76: 1079–1084.[CrossRef][Medline] [Order article via Infotrieve]
24. Okazaki H, Hirata D, Kamimura T, Sato H, Iwamoto M, Yoshio, Masuyama J, Fujimura A, Kobayashi E, Kano S, Minota S. Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus. J Rheumatol. 2002; 29: 707–716.
25. Kohno T, Tsuji T, Hirayama K, Iwatsuki R, Hirose M, Watabe K, Yoshikawa H, Kohno T, Matsumoto A, Fujita T, Hayashi M. A novel immunomodulator, FTY720, prevents development of experimental autoimmune myasthenia gravis in C57BL/6 mice. Biol Pharm Bull. 2005; 28: 736–739.[CrossRef][Medline] [Order article via Infotrieve]
26. Donners MM, Bot I, De Windt LJ, van Berkel TJ, Daemen MJ, Biessen EA, Heeneman S. Low-dose FK506 blocks collar-induced atherosclerotic plaque development and stabilizes plaques in ApoE-/- mice. Am J Transplant. 2005; 5: 1204–1215.[CrossRef][Medline] [Order article via Infotrieve]
27. Bot I, von der Thusen JH, Donners MM, Lucas A, Fekkes ML, de Jager SC, Kuiper J, Daemen MJ, van Berkel TJ, Heeneman S, Biessen EA. Serine protease inhibitor Serp-1 strongly impairs atherosclerotic lesion formation and induces a stable plaque phenotype in ApoE-/-mice. Circ Res. 2003; 93: 464–471.
28. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004; 25: 677–686.[CrossRef][Medline] [Order article via Infotrieve]
29. Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, Brinkmann V, Allende ML, Proia RL, Cyster JG. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature. 2004; 427: 355–360.[CrossRef][Medline] [Order article via Infotrieve]
30. Dansky HM, Charlton SA, Harper MM, Smith JD. T and B lymphocytes play a minor role in atherosclerotic plaque formation in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci U S A. 1997; 94: 4642–4646.
31. Zhou X, Nicoletti A, Elhage R, Hansson GK. Transfer of CD4(+) T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation. 2000; 102: 2919–2922.
32. Reardon CA, Blachowicz L, White T, Cabana V, Wang Y, Lukens J, Bluestone J, Getz GS. Effect of immune deficiency on lipoproteins and atherosclerosis in male apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2001; 21: 1011–1016.
33. Zhou X, Robertson AK, Rudling M, Parini P, Hansson GK. Lesion development and response to immunization reveal a complex role for CD4 in atherosclerosis. Circ Res. 2005; 96: 427–434.
34. Zhou X, Robertson AK, Hjerpe C, Hansson GK. Adoptive transfer of CD4+ T cells reactive to modified low-density lipoprotein aggravates atherosclerosis. Arterioscler Thromb Vasc Biol. 2006; 26: 864–870.
35. Dorsam G, Graeler MH, Seroogy C, Kong Y, Voice JK, Goetzl EJ. Transduction of multiple effects of sphingosine 1-phosphate (S1P) on T cell functions by the S1P1 G protein-coupled receptor. J Immunol. 2003; 171: 3500–3507.
36. Wang W, Graeler MH, Goetzl EJ. Type 4 sphingosine 1-phosphate G protein-coupled receptor (S1P4) transduces S1P effects on T cell proliferation and cytokine secretion without signaling migration. FASEB J. 2005; 19: 1731–1733.
37. Jin Y, Knudsen E, Wang L, Bryceson Y, Damaj B, Gessani S, Maghazachi AA. Sphingosine 1-phosphate is a novel inhibitor of T-cell proliferation. Blood. 2003; 101: 4909–4915.
38. Stemme S, Holm J, Hansson GK. T lymphocytes in human atherosclerotic plaques are memory cells expressing CD45RO and the integrin VLA-1. Arterioscler Thromb. 1992; 12: 206–211.
39. Whitman SC, Ravisankar P, Daugherty A. IFN-gamma deficiency exerts gender-specific effects on atherogenesis in apolipoprotein E-/- mice. J Interferon Cytokine Res. 2002; 22: 661–670.[CrossRef][Medline] [Order article via Infotrieve]
40. Gupta S, Pablo AM, Jiang X, Wang N, Tall AR, Schindler C. IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. J Clin Invest. 1997; 99: 2752–2761.[Medline] [Order article via Infotrieve]
41. Whitman SC, Ravisankar P, Elam H, Daugherty A. Exogenous interferon-gamma enhances atherosclerosis in apolipoprotein E-/- mice. Am J Pathol. 2000; 157: 1819–1824.
42. Man K, Ng KT, Lee TK, Lo CM, Sun CK, Li XL, Zhao Y, Ho JW, Fan ST. FTY720 attenuates hepatic ischemia-reperfusion injury in normal and cirrhotic livers. Am J Transplant. 2005; 5: 40–49.[CrossRef][Medline] [Order article via Infotrieve]
43. Graler MH, Huang MC, Watson S, Goetzl EJ. Immunological effects of transgenic constitutive expression of the type 1 sphingosine 1-phosphate receptor by mouse lymphocytes. J Immunol. 2005; 174: 1997–2003.
44. Wang W, Graeler MH, Goetzl EJ. Physiological sphingosine 1-phosphate requirement for optimal activity of mouse CD4+ regulatory T Cells. FASEB J. 2004; 18: 1043–1045.
45. Zhou X, Paulsson G, Stemme S, Hansson GK. Hypercholesterolemia is associated with a T helper (Th) 1/Th2 switch of the autoimmune response in atherosclerotic apo E-knockout mice. J Clin Invest. 1998; 101: 1717–1725.[Medline] [Order article via Infotrieve]
46. Singleton PA, Dudek SM, Chiang ET, Garcia JG. Regulation of sphingosine 1-phosphate-induced endothelial cytoskeletal rearrangement and barrier enhancement by S1P1 receptor, PI3 kinase, Tiam1/Rac1, and alpha-actinin. FASEB J. 2005; 19: 1646–1656.
47. Bolick DT, Srinivasan S, Kim KW, Hatley ME, Clemens JJ, Whetzel A, Ferger N, Macdonald TL, Davis MD, Tsao PS, Lynch KR, Hedrick CC. Sphingosine-1-phosphate prevents tumor necrosis factor-{alpha}-mediated monocyte adhesion to aortic endothelium in mice. Arterioscler Thromb Vasc Biol. 2005; 25: 976–981.
48. Chi H, Flavell RA. Cutting edge: regulation of T cell trafficking and primary immune responses by sphingosine 1-phosphate receptor 1. J Immunol. 2005; 174: 2485–2488.
49. Man K, Ng KT, Lee TK, Lo CM, Sun CK, Li XL, Zhao Y, Ho JW, Fan ST. FTY720 attenuates hepatic ischemia-reperfusion injury in normal and cirrhotic livers. Am J Transplant. 2005; 5: 40–49.[CrossRef][Medline] [Order article via Infotrieve]
50. Awad AS, Ye H, Huang L, Li L, Foss Jr FW, Macdonald TL, Lynch KR, Okusa MD. Selective sphingosine 1-phosphate 1 (S1P1) receptor activation reduces ischemia-reperfusion injury in mouse kidney. Am J Physiol Renal Physiol. 2006; 290: F1516–F1524.
51. Calabresi L, Rossoni G, Gomaraschi M, Sisto F, Berti F, Franceschini G. High-density lipoproteins protect isolated rat hearts from ischemia-reperfusion injury by reducing cardiac tumor necrosis factor-alpha content and enhancing prostaglandin release. Circ Res. 2003; 92: 330–337.
52. Thiemermann C, Patel NS, Kvale EO, Cockerill GW, Brown PA, Stewart KN, Cuzzocrea S, Britti D, Mota-Filipe H, Chatterjee K. High density lipoprotein (HDL) reduces renal ischemia/reperfusion injury. J Am Soc Nephrol. 2003; 14: 1833–1843.
53. Theilmeier G, Schmidt C, Herrmann J, Keul P, Schafers, Herrgott I, Mersmann J, Larmann J, Hermann S, Stypmann J, Schober O, Hildebrand R, Schulz R, Heusch G, Haude M, von Wnuck Lipinski K, Herzog C, Schmitz M, Erbel R, Chun J, Levkau B. High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor. Circulation. 2006; 114: 1403–1409.
|
Footnotes |
|---|
*The first 2 authors contributed equally to this article.
The online-only Data Supplement, consisting of an expanded Methods section, is available with this article at http://circ.ahajournals. org/cgi/content/full/CIRCULATIONAHA.106.641407/DC1.
This article has been cited by other articles:
 |
|
 |
|
  G. Daum, A. Grabski, and M.A. Reidy Sphingosine 1-Phosphate: A Regulator of Arterial Lesions Arterioscler Thromb Vasc Biol, October 1, 2009; 29(10): 1439 - 1443. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kramer, E. Binder, T. Loof, Y. Wang-Rosenke, S. Martini, D. Khadzhynov, K. Budde, H.-H. Neumayer, and H. Peters The lymphocyte migration inhibitor FTY720 attenuates experimental hypertensive nephropathy Am J Physiol Renal Physiol, July 1, 2009; 297(1): F218 - F227. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Sattler and B. Levkau Sphingosine-1-phosphate as a mediator of high-density lipoprotein effects in cardiovascular protection Cardiovasc Res, May 1, 2009; 82(2): 201 - 211. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L.E. MacDonald, M. van Eck, R. B. Hildebrand, B. W.C. Wong, N. Bissada, P. Ruddle, A. Kontush, H. Hussein, M. A. Pouladi, M. J. Chapman, et al. Despite Antiatherogenic Metabolic Characteristics, SCD1-Deficient Mice Have Increased Inflammation and Atherosclerosis Arterioscler Thromb Vasc Biol, March 1, 2009; 29(3): 341 - 347. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-i. Takashima, N. Sugimoto, N. Takuwa, Y. Okamoto, K. Yoshioka, M. Takamura, S. Takata, S. Kaneko, and Y. Takuwa G12/13 and Gq mediate S1P2-induced inhibition of Rac and migration in vascular smooth muscle in a manner dependent on Rho but not Rho kinase Cardiovasc Res, September 1, 2008; 79(4): 689 - 697. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Hughes, S. Srinivasan, K. R. Lynch, R. L. Proia, P. Ferdek, and C. C. Hedrick Sphingosine-1-Phosphate Induces an Antiinflammatory Phenotype in Macrophages Circ. Res., April 25, 2008; 102(8): 950 - 958. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Srinivasan, D. T. Bolick, D. Lukashev, C. Lappas, M. Sitkovsky, K. R. Lynch, and C. C. Hedrick Sphingosine-1-Phosphate Reduces CD4+ T-Cell Activation in Type 1 Diabetes Through Regulation of Hypoxia-Inducible Factor Short Isoform I.1 and CD69 Diabetes, February 1, 2008; 57(2): 484 - 493. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Argraves and W. S. Argraves HDL serves as a S1P signaling platform mediating a multitude of cardiovascular effects J. Lipid Res., November 1, 2007; 48(11): 2325 - 2333. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Klingenberg, J.-R. Nofer, M. Rudling, F. Bea, E. Blessing, M. Preusch, H. J. Grone, H. A. Katus, G. K. Hansson, and T. J. Dengler Sphingosine-1-Phosphate Analogue FTY720 Causes Lymphocyte Redistribution and Hypercholesterolemia in ApoE-Deficient Mice Arterioscler Thromb Vasc Biol, November 1, 2007; 27(11): 2392 - 2399. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||